Former California biotech executive convicted of fraud in marketing of Actimmune drugOctober 3rd, 2009 Calif. biotech exec convicted of marketing fraudSAN FRANCISCO — The former chief executive of the biotechnology company InterMune Inc. has been convicted of wire fraud in marketing the drug Actimmune.
S&P removes drugmaker Wyeth from 2 indices in sign $68B acquisition by Pfizer will go throughOctober 2nd, 2009 S&P removes Wyeth from indices before acquisitionTRENTON, N.J. — In the latest sign that Pfizer Inc.'s $68 billion purchase of Wyeth will go through, Wyeth's stock has been removed from two key investor indices.
Pfizer's $68 billion buyout of Wyeth gets clearance in Australia, still awaiting US clearanceSeptember 30th, 2009 Pfizer, Wyeth deal gets clearance in AustraliaNEW YORK — Drug developer Pfizer says the Australian Competition and Consumer Commission approved the company's $68 billion buyout of rival Wyeth. Pfizer will divest certain animal health assets in Australia, the New York-based company says.
Pfizer's $68 billion buyout of Wyeth gets clearance in China, still awaiting US clearanceSeptember 30th, 2009 Pfizer, Wyeth deal gets clearance in ChinaNEW YORK — Drug developer Pfizer Inc. said Tuesday China's ministry of commerce approved the company's $68 billion buyout of rival Wyeth.
Pfizer to pay record $2.3 billion settlement for illegal drug promotionSeptember 2nd, 2009 Pfizer to pay record $2.3 billion settlementWASHINGTON — People familiar with a record legal settlement to be announced Wednesday say that Pfizer Inc., the world's largest drugmaker, will pay $2.3 billion in connection with illegal drug promotions. The U.S. Justice Department plans a news conference later in the day to announce the terms of the deal.
Merck & Co. shareholders OK $41.1 billion acquisition of partner drugmaker Schering-PloughAugust 7th, 2009 Merck shareholders OK Schering-Plough purchaseTRENTON, N.J. — Shareholders of drugmaker Merck & Co.
Merck, Schering-Plough shareholders back $41.1 billion combo to create world's No. 2 drugmakerAugust 7th, 2009 Merck, Schering-Plough shareholders OK $41B dealTRENTON, N.J. — Shareholders of drugmakers Merck & Co.
Cardinal says it paid undisclosed amount for radiologic dye and scanning company BiotechAugust 3rd, 2009 Cardinal Health buys imaging company BiotechDUBLIN, Ohio — Cardinal Health Inc. said Monday it agreed to buy radiologic imaging company Biotech for an undisclosed amount.
98 percent of shareholders of drugmaker Wyeth vote to be acquired by industry giant PfizerJuly 20th, 2009 Wyeth shareholders vote to be acquired by PfizerTRENTON, N.J. — Shareholders of drugmaker Wyeth on Monday voted overwhelmingly to be bought by industry giant Pfizer Inc., pushing aside one of the deal's final hurdles.
EU says Pfizer is suggesting changes to Wyeth bid to win regulatory approvalJune 30th, 2009 EU: Pfizer promising changes to Wyeth bidBRUSSELS — U.S. drug maker Pfizer Inc.
Drugmaker Wyeth sets July annual meeting for shareholders to vote on acquisition by PfizerJune 18th, 2009 Wyeth sets meeting for shareholders' merger voteMORRISTOWN, N.J. — Wyeth has scheduled a meeting for the drugmaker's shareholders to vote whether to approve its pending acquisition by drug giant Pfizer.
Indian biotech industry growing, but at slower paceJune 18th, 2009 BANGALORE - Global recession and slowdown in the domestic market impacted the Indian biotech industry last fiscal, resulting in a year-on-year (YoY) growth declining to 18 percent from 34 percent notched in 2007-08. According to data released Thursday at Bangalore Bio 2009, India's premier biotech event, the industry grew to Rs.12,137 crore from Rs.10,274 crore the previous fiscal, reflecting an increase of 18 percent.
Drugmaker Pfizer's Q1 profit dips 2 percent on much lower sales, costs of Wyeth acquisitionApril 28th, 2009 Pfizer profit dips 2 percent, sales fall much moreNEW YORK — Pfizer Inc. posts a 2 percent drop in first-quarter profit, as cost-cutting by the world's largest drugmaker couldn't offset big drops in sales for several medicines.
Pfizer offers Rs.6.8 bn to raise stake in Indian armApril 13th, 2009 MUMBAI - Global pharmaceutical major Pfizer Monday said it will make an offer to acquire a further 33.77 percent in its Indian subsidiary Pfizer Ltd for Rs.6.8 billion. The acquisition will raise its stake to 75 percent.
Pfizer to make tender offer to increase stake in Pfizer LimitedApril 13th, 2009 MUMBAI - Pfizer Investments Netherlands B.V., an indirect wholly-owned subsidiary of Pfizer Inc, today announced that it will make a tender offer to acquire a 33.77 per cent stake in Pfizer Limited from public shareholders at a price of Rs. 675.00 per share.
Loading ...